Saturday, 31 October 2026European Markets

BELUGA Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of BELUGA (BEL 20: BELU.BR) dropped by a staggering 16.67% in 5 sessions from €3 to €2.50 at 05:11 EST on Wednesday, after five successive sessions in a row of losses. BEL 20 is rising 0.79% to €3,534.85, after three successive sessions in a row of gains.

About BELUGA

Beluga NV is a private equity and venture capital firm specializing in investments in mid venture, late venture, middle market, and mature companies. It also invests in growth capital, later stages, and buyouts. The firm invests across all sectors in companies based in Belgium with a focus on the Flanders region. It usually invests between €0.25 million ($0.37 million) and €2.5 million ($3.75 million) in the form of a minority stake in both public and private companies. The firm typically invests in companies with enterprise value between €1 million ($1.50 million) and €250 million ($375.7 million), sales values between €0.25 million ($0.37 million) and €500 million ($751.41 million), and EBITDA values between €1 million ($1.50 million) and €100 million ($150.28 million). The firm sources its capital through the stock market. Beluga NV was founded in 1998 and is based in Ternat, Belgium.

Earnings Per Share

As for profitability, BELUGA has a trailing twelve months EPS of €0.02.

PE Ratio

BELUGA has a trailing twelve months price to earnings ratio of 125. Meaning, the purchaser of the share is investing €125 for every euro of annual earnings.

Volatility

BELUGA's last week, last month's, and last quarter's current intraday variation average was a negative 20.00%, a negative 3.47%, and a positive 26.39%.

BELUGA's highest amplitude of average volatility was 20.00% (last week), 16.80% (last month), and 26.39% (last quarter).

More news about BELUGA (BELU.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com